Evidence map›Paper›PMID 41395630›Full record

ArticleFrontiers in digital health2025

UpSMART: five years of digital innovation in cancer clinical research-achievements, challenges, and recommendations.

Paul O'Regan, Fouziah Butt, Louise Carter, Donna M Graham, Anja Le Blanc, Richard Hoskins, Laura Stephenson, Akshita Patil, Muhammad Shabbir, Dilan Eken and 12 more

Abstract read
In one paragraph

Article in Frontiers in digital health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Paul O'ReganDigital Cancer Research Team, CRUK National Biomarker Centre, The University of Manchester, Manchester, United Kingdom.
Fouziah ButtDigital Cancer Research Team, CRUK National Biomarker Centre, The University of Manchester, Manchester, United Kingdom.
Louise CarterDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
Donna M GrahamDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
Anja Le BlancDigital Cancer Research Team, CRUK National Biomarker Centre, The University of Manchester, Manchester, United Kingdom.
Richard HoskinsDigital Cancer Research Team, CRUK National Biomarker Centre, The University of Manchester, Manchester, United Kingdom.
Laura StephensonDigital Cancer Research Team, CRUK National Biomarker Centre, The University of Manchester, Manchester, United Kingdom.
Akshita PatilDigital Cancer Research Team, CRUK National Biomarker Centre, The University of Manchester, Manchester, United Kingdom.
Muhammad ShabbirResearch IT, The University of Manchester, Manchester, United Kingdom.
Dilan EkenDigital Cancer Research Team, CRUK National Biomarker Centre, The University of Manchester, Manchester, United Kingdom.
Subir SinghDigital Cancer Research Team, CRUK National Biomarker Centre, The University of Manchester, Manchester, United Kingdom.
Andrea VillaDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Luca AgnelliDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Silvia DamianDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Christopher GraveResearch IT, The University of Manchester, Manchester, United Kingdom.
Giulia PretelliEarly Drug Development, Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Elena GarraldaEarly Drug Development, Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Hannah FrostDigital Cancer Research Team, CRUK National Biomarker Centre, The University of Manchester, Manchester, United Kingdom.
Filippo de BraudDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Andre FreitasDepartment of Computer Science, The University of Manchester, Manchester, United Kingdom.
Caroline DiveCancer Research UK National Biomarker Centre, The University of Manchester, Manchester, United Kingdom.
Harriet UnsworthDigital Cancer Research Team, CRUK National Biomarker Centre, The University of Manchester, Manchester, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

UpSMART, a research programme involving 24 European cancer centres, aimed to promote digital innovation in early-phase clinical research addressing challenges in recruitment, data collection and analysis. Several open-source digital healthcare products (DHPs) were developed through UpSMART, including eTARGET and trialFinder for trial matching, and PROACT 2.0 for patient-reported data. Lessons learned highlight the importance of multidisciplinary teams, sustainable funding and deployment, and engagement with the research community to maximise impact.

Indexed as

cancer clinical trialsclinical trial innovationdigital healthcare productsdigital health technologiesopen-source

Identifiers

PMID41395630
PMCPMC12697062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.